株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

北米のドラッグデリバリー技術市場の予測 - 定量吸入器、無針注射器、自動注射装置、鼻内噴霧器、経皮パッチ、ネブライザー、注入ポンプ、薬剤溶出ステント、徐放薬、眼内インプラント

North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 2017

発行 MarketsandMarkets 商品コード 276289
出版日 ページ情報 英文 267 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
北米のドラッグデリバリー技術市場の予測 - 定量吸入器、無針注射器、自動注射装置、鼻内噴霧器、経皮パッチ、ネブライザー、注入ポンプ、薬剤溶出ステント、徐放薬、眼内インプラント North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 2017
出版日: 2013年07月12日 ページ情報: 英文 267 Pages
概要

医薬品メーカーにとって主力薬品の特許失効は大きな悩みのひとつ。そうしたなか、新規化学物質(NCE)ではなく、ドラッグデリバリー(ドラッグデリバリー)技術を開発する作業なら、費用・時間のいずれにおいても負担は軽度です。そこで近年、数社の医薬品メーカーは、新たな送達技術を導入することで、特許失効を目前に控えた主力商品の延命を図る方策をとりました。北米の薬物市場は、2012年実績で667億ドル規模。以降、8.9%の複合年間成長率を維持するものと推定されます。

当レポートでは、北米のドラッグデリバリー技術市場に注目し、投与法および国(米国およびカナダ)別に市場取引額の推移を検証・予測するほか、市場の推進・抑制要因、成長機会と課題、競合環境、主要参入企業などについての最新情報を集めて、概略以下の構成でお届けします。

第1章 イントロダクション

  • 重要所見
  • レポート内容
  • 調査対象市場
  • レポートの推奨利用者層
  • 調査方法
    • 市場規模
    • 市場シェア
    • 二次情報源から得られたデータの重要ポイント
    • 一次情報源から得られたデータの重要ポイント
    • 前提

第2章 エグゼクティブサマリー

第3章 市場概要

  • イントロダクション
  • 市場セグメンテーション
  • 市場動態
    • 推進要因
      • 「特許の崖」と競争激化で上昇する利用率
      • 患者の服用順守および容認度向上で弾みがつくドラッグデリバリー装置市場
      • 北米で高まる小児および高齢患者重視の姿勢から成長が加速
      • 北米における慢性疾患蔓延で増大する需要
    • 抑制要因
      • 市場の成長を妨げる欠陥薬剤とリコール
      • 技法上の障壁が成長の足かせに
    • 機会
      • 医薬品メーカーとドラッグデリバリー企業の協力
      • 自己投与および在宅介護ドラッグデリバリー装置
      • 拡大しつつあるドラッグデリバリー技術の適用範囲
    • 標的ドラッグデリバリー
      • 標的ドラッグデリバリー市場の6割を占める受動的システム
      • がん治療を主要用途とする能動的標的ドラッグデリバリー
      • 企業は新規の標的ドラッグデリバリー技術に注目
    • 緊急課題
      • 新鮮で適正な企業連携
      • 薬物の生体内利用度向上
    • 規制環境
      • 医薬品に厳しい規制を設ける北米
      • 米国医療改革がドラッグデリバリー産業に与える影響
      • 徐放薬承認に関連する規制
    • Porterのファイブフォース分析
    • バリューチェーン分析
    • 市場シェア分析
      • 経肺ドラッグデリバリー
      • 経皮ドラッグデリバリー
      • 注射型ドラッグデリバリー
      • インプラント型ドラッグデリバリー
      • その他のドラッグデリバリーセグメント

第4章 北米のドラッグデリバリー市場 - 技術別

  • イントロダクション
  • 技術進歩を迎えるドラッグデリバリー市場
  • 機会マトリクス
  • 経口ドラッグデリバリー
  • 経肺ドラッグデリバリー
  • 経皮ドラッグデリバリー
  • 注射型ドラッグデリバリー
  • 眼内ドラッグデリバリー
  • 鼻内ドラッグデリバリー
  • 局所ドラッグデリバリー
  • インプラント型ドラッグデリバリー
  • 経粘膜ドラッグデリバリー

第5章 地域分析

  • イントロダクション
  • 米国
  • カナダ

第6章 競合環境

  • イントロダクション
  • M&A
  • 協定、協力、合弁事業、提携関係
  • 新製品発売
  • その他の展開

第10章 企業プロフィール(概要、財務、製品・サービス、戦略、事業展開)

目次
Product Code: BT 2077

Abstract

Report Descriptioon

Patent expiry of major blockbuster drugs is a prime concern for pharmaceutical companies, as developing a new chemical entity (NCE) is more expensive and time consuming than a novel drug delivery technology. Therefore, in recent years, several pharmaceutical companies have employed drug delivery technology as a life cycle management tool for some of their blockbuster drugs, the patents for which are set to expire in the near future.

The North American drug delivery market was estimated to be worth $66.7 billion in 2012, and is expected to register a CAGR of 8.9% between 2012 and 2017. Based on the route of administration, the drug delivery market has been classified as oral, pulmonary, injectable, transdermal, implantable, ocular, nasal, transmucosal, and topical. In 2012, oral drug delivery segment dominated the market with a share of approximately 38%, followed by pulmonary drug delivery segment with a 20% share.

The drug delivery technologies that have recently gained importance in the North American market include orodispersible tablet (ODT), dry powder inhalers, transdermal patches, needle-free injectors, auto and pen injectors, and buccal transmucosal tablets; controlled release is the most widely accepted technology. The use of implantable devices for drug delivery is also on a rise.

Big pharmaceutical companies such as Pfizer and Merck have established in-house capabilities for the development of drug delivery technologies. On the contrary, many other companies are still relying on specialty companies engaged in the development of drug delivery technologies. High level of competition and increasing need for outsourcing has resulted in the drug delivery market to be fragmented, with several small companies developing novel drug delivery technologies for niche therapeutic applications.

The North American drug delivery market is largely dominated by the U.S. (accounting for about 89% of the overall market). The key drivers for the U.S. drug delivery market are the well established pharmaceutical industry , healthcare reforms, and favourable changes in the FDA review process. Factors such as low cost drug manufacturing and rising number of drug delivery formulations and devices are propelling the Canadian market.

Key players in the drug delivery technologies market are 3M Company (U.S.), Aptalis Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton, Dickinson & Co. (U.S.), Catalent Pharma Solutions (U.S.), The Dow Chemical Company (U.S.), Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics (U.S.) and Valeant Pharmaceuticals (Canada).

Scope of the Report

This research report categorizes and analyzes the North American Drug Delivery Technologies market on the basis of routes of administration. These markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S and Canada), to provide in-depth information on the North American market scenario.

North American drug delivery technologies market, by segment:

  • Oral Drug Delivery
    • Controlled Release
    • Orodispersible Tablets (ODT) and Taste Masking
    • Others
  • Pulmonary Drug Delivery
    • Dry Powder Inhalers
    • Metered Dose Inhalers
    • Nebulizers
  • Transdermal Drug Delivery
    • Passive Drug Delivery
      • Reservoir System
      • Matrix System
    • Active Drug Delivery
      • Iontophoresis
      • Microporation
      • Others
  • Injectable Drug Delivery
    • Conventional Injection Devices
      • Fillable Syringes
      • Prefilled Syringes
    • Self-injection Devices
      • Needle-free Injectors
      • Auto-injectors or Safety Syringe Devices
      • Pen Injectors
    • Others
  • Ocular Drug Delivery
    • Eye Drops
    • Ointment and Gel
    • Others
  • Nasal Drug Delivery
    • Nasal Drops
    • Nasal Sprays
    • Nasal Inhalers
    • Others
  • Topical Drug Delivery
    • Liquid Formulations
    • Semisolid Formulations
    • Solid Formulations
  • Implantable Drug Delivery
    • Drug-Eluting Stents
    • Implantable Infusion Pumps
    • Contraceptive Implants
    • Intravitreal Implants
    • Brachytherapy Seeds
  • Transmucosal Drug Delivery
    • Oral (Buccal and Sublingual)
    • Others (Rectal and Vaginal)

North America drug delivery technologies market, by country:

  • U.S
  • Canada

Summary

The North American Drug Delivery Technologies Market report (2012-2017) covers the market for technologies used for development of products, formulations, and devices used in drug delivery. The overall market is segmented based on the oral, pulmonary, trandermal, injectable, ocular, nasal, topical, implantable, and transmucosal routes of administration used by these technologies. Oral drug delivery technologies accounted for the largest share - 38% - of the North American market in 2012, under which controlled release and orodispersible tablet technologies and other technologies such as effervescent tablets and chewable tablets are covered.

Pulmonary segment covers metered dose inhalers, dry-powder inhalers and nebulizers; this segment is growing at the highest CAGR of 11.8%. The transdermal technology market is divided into two types, namely, passive drug delivery and active drug delivery. Passive delivery is further categorized into reservoir system and matrix system, while active delivery is further categorized into iontophoresis, microporation and other technologies such as electroporation, sonophoresis and dermal ablation. Injectable technology market is classified as conventional injection, self injection, and other injection devices. Conventional devices include fillable syringes and prefilled syringes, whereas self injection devices include needle free injectors, auto-injectors, and pen injectors.

Ocular drug delivery technologies market is divided into eye drops, ophthalmic ointments, gels and other formulations like ocular inserts and punctal plugs. Based on the type of formulation, nasal drug delivery technologies market is categorized into nasal drops, sprays, and inhalers. Based on formulation type, topical drug delivery technologies market is segmented into liquid, semisolid, and solid formulations. Implantable technologies market is divided into drug eluting stents, infusion pumps, intraocular implants, brachytherapy seeds, and contraceptive implants. Transmucosal drug delivery technologies market is categorized into two segments, namely, oral transmucosal technologies (buccal and sublingual delivery) and other transmucosal technologies (rectal and vaginal formulations).

The report also covers the market by two major countries in North America, namely, the U.S and Canada. The U.S. certainly leads the market with a share of 89%, owing to the well-established pharmaceutical industries and transformations in the U.S. FDA review processes. Canada is witnessing a rise in drug approvals and partnerships related to drug delivery technologies.

The increasing number of big pharma firms indulging in reformulation strategies and the rising costs of patient non-compliance in the U.S. are some of the factors that are driving the North American market. Development of home care drug delivery systems and rise in the number of therapeutic applications are some of the factors that open avenues for drug delivery market.

Key players in the market are 3M Company (U.S.), Aptalis Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton Dickinson & Co. (U.S.), Catalent Pharma Solutions (U.S.), Cipher Pharmaceuticals (Canada), Dow Chemical Company (U.S.), Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics (U.S.), OptiNose (U.S.), QLT (Canada), and Valeant Pharmaceuticals (Canada).

image1

Table of Contents

1 Introduction

  • 1.1 Key Take-Aways
  • 1.2 Report Description
  • 1.3 Markets Covered
  • 1.4 Stakeholders
  • 1.5 Research Methodology
    • 1.5.1 Market Size
    • 1.5.2 Market Share
    • 1.5.3 Key Data Points From Secondary Sources
    • 1.5.4 Key Data Points From Primary Sources
    • 1.5.5 Assumptions

2 Executive Summary

3 Market Overview

  • 3.1 Introduction
  • 3.2 Market Segmentation
  • 3.3 Market Dynamics
    • 3.3.1 Drivers
      • 3.3.1.1 Patent Cliff And Increased Competition To Increase Adoption Rate
      • 3.3.1.2 Improving Patient Compliance And Acceptability, An Impetus To The Drug Delivery Systems Market
      • 3.3.1.3 Increasing Focus On Pediatric And Geriatric Patients To Boost The Growth
      • 3.3.1.4 Increasing Incidence Of Chronic Diseases In North America To Enhance Demand
    • 3.3.2 Restraints
      • 3.3.2.1 Drug Failures And Recalls Mar Market Growth
      • 3.3.2.2 Technical Barriers Restrict Growth
    • 3.3.3 Opportunities
      • 3.3.3.1 Collaborations Between Pharmaceutical Companies And Drug Delivery Firms
      • 3.3.3.2 Self-Administration And Home Care Drug Delivery Devices
      • 3.3.3.3 Expanding Therapeutic Applications Of Drug Delivery Technologies
    • 3.3.4 Targeted Drug Delivery
      • 3.3.4.1 Passive Systems Contribute 60% To The Targeted Drug Delivery Market
      • 3.3.4.2 Active Targeted Drug Delivery Has Major Applications In Cancer Therapy
      • 3.3.4.3 Companies Focus On Novel Targeted Drug Delivery
    • 3.3.5 Burning Issues
      • 3.3.5.1 Striking Right Partnerships
      • 3.3.5.2 Improving The Bioavailability Of Drugs
  • 3.4 Regulatory Environment
    • 3.4.1 Stringent Regulations For Pharmaceutical Drugs In North America
      • 3.4.1.1 The Approval Process Is Complex, Time-Consuming, And Expensive
    • 3.4.2 Effect Of The U.S. Healthcare Reforms On The Drug Delivery Industry
      • 3.4.2.1 Drug Delivery Companies To Benefit From The Affordable Care Act (Aca) Reform In The Long Run
    • 3.4.3 Regulations Related To The Approval Of Controlled Release Drugs
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Threat Of New Entrants
    • 3.5.2 Threat Of Substitutes
    • 3.5.3 Competitor's Rivalry
    • 3.5.4 Bargaining Power Of Suppliers
    • 3.5.5 Bargaining Power Of Buyers
  • 3.6 Value Chain Analysis
  • 3.7 Market Share Analysis
    • 3.7.1 Pulmonary Drug Delivery
      • 3.7.1.1 U.S.
      • 3.7.1.2 Canada
    • 3.7.2 Transdermal Drug Delivery
      • 3.7.2.1 U.S.
      • 3.7.2.2 Canada
    • 3.7.3 Inectable Drug Delivery Devices
      • 3.7.3.1 U.S.
      • 3.7.3.2 Canada
    • 3.7.4 Implantable Drug Delivery
      • 3.7.4.1 U.S.
      • 3.7.4.2 Canada
    • 3.7.5 Other Drug Delivery Segments

4 North America Drug Delivery Market, By Technology

  • 4.1 Introduction
    • 4.1.1 Drug Delivery Market Witnessing Technological Advancements
  • 4.2 Opportunity Matrix
  • 4.3 Oral Drug Delivery
    • 4.3.1 Reformulation Strategies & Establishing In-House Capabilities Help In Significant Growth
    • 4.3.2 Controlled Release
    • 4.3.3 Orodispersible Tablets (ODT) And Taste Masking
    • 4.3.4 Others
  • 4.4 Pulmonary Drug Delivery
    • 4.4.1 Therapeutic Applications Of Pulmonary Delivery
    • 4.4.1.1 Application Of Pulmonary Delivery For Non-Respiratory Therapies Is A Growing Opportunity
    • 4.4.2 Metered Dose Inhalers (MDI)
    • 4.4.3 Dry Powder Inhalers (DPI)
    • 4.4.4 Nebulizers
  • 4.5 Transdermal Drug Delivery
    • 4.5.1 Passive Transdermal Drug Delivery
      • 4.5.1.1 Matrix System
      • 4.5.1.2 Reservoir System
    • 4.5.2 Active Transdermal Drug Delivery
      • 4.5.2.1 Microporation
      • 4.5.2.2 Iontophoresis
      • 4.5.2.3 Others
  • 4.6 Injectable Drug Delivery
    • 4.6.1 Injectable Drug Delivery Market Witnessing Developments Related To Product Improvement
    • 4.6.2 Conventional Injectable Drug Delivery Devices
      • 4.6.2.1 Low Manufacturing Cost And Affordable Prices: Key Driver For Conventional Injection Devices
      • 4.6.2.2 Fillable
      • 4.6.2.3 Prefilled
    • 4.6.3 Self-Injection Devices
      • 4.6.3.1 Self-Injection Devices Reduce Overall Treatment Cost
      • 4.6.3.2 Pen Injectors
      • 4.6.3.3 Needle-Free Injectors
      • 4.6.3.4 Auto Injectors
    • 4.6.4 Others
  • 4.7 Ocular Drug Delivery
    • 4.7.1 Eye Drops
    • 4.7.2 Ointments And Gels
    • 4.7.3 Others
  • 4.8 Nasal Drug Delivery
    • 4.8.1 Nasal Drug Delivery Preferred For Locally Acting Drugs And Delivery Of Vaccines
    • 4.8.2 Nasal Sprays
    • 4.8.3 Nasal Inhalers
    • 4.8.4 Nasal Drops
    • 4.8.5 Others
  • 4.9 Topical Drug Delivery
    • 4.9.1 Topical Delivery Majorly Adopted For Dermatology Drugs
    • 4.9.2 Semi-Solid Formulations
    • 4.9.3 Liquid Formulations
    • 4.9.4 Solid Formulations
  • 4.10 Implantable Drug Delivery
    • 4.10.1 Drug- Eluting Stents
    • 4.10.2 Implantable Infusion Pumps
      • 4.10.2.1 Implantable Infusion Pumps Largely Used For Therapies Of Chronic Ailments
    • 4.10.3 Contraceptive Implants
    • 4.10.4 Intravitreal Implants
    • 4.10.5 Brachytherapy Seeds
  • 4.11 Transmucosal Drug Delivery
    • 4.11.1 Oral (Buccal And Sublingual)
    • 4.11.2 Others (Rectal, Vaginal)

5 Geographic Analysis

  • 5.1 Introduction
  • 5.2 United States
    • 5.2.1 Well-Established U.S. Pharmaceutical Industry Drives The Drug Delivery Market
    • 5.2.2 Favorable Changes In The Fda To Accelerate Drug Review And Approval Processes
    • 5.2.3 U.S. Healthcare Reforms Will Impact The Drug Delivery Market
  • 5.3 Canada
    • 5.3.1 Insurance Coverage Favoring The Growth Of Canadian Drug Delivery Technology Market
    • 5.3.2 Rise In Number Of Approvals And Agreements In The Canada Drug Delivery Market

6 Competitive Landscape

  • 6.1 Introduction
    • 6.1.1 Mergers & Acquisitions And Agreements & Collaborations Were The Key Strategies Adopted By Players
  • 6.2 Mergers & Acquisitions
  • 6.3 Agreements, Collaborations, Joint Ventures & Partnerships
  • 6.4 New Product Launch
  • 6.5 Other Developments

7 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 7.1 3M Company
  • 7.2 Aptalis Pharma, Inc.
  • 7.3 Baxter International, Inc.
  • 7.4 Becton, Dickinson And Company
  • 7.5 Catalent Pharma Solutions
  • 7.6 Cima Labs
  • 7.7 Endo Health Solutions, Inc.
  • 7.8 Johnson & Johnson, Inc.
  • 7.9 Nektar Therapeutics, Inc.
  • 7.10 Optinose As
  • 7.11 Psivida Corporation
  • 7.12 The Dow Chemical Company
  • 7.13 Valeant Pharmaceuticals

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

List of Tables

  • Table 1 North America Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 2 Key Drug Delivery Technology Providers & Marketer Companies
  • Table 3 North American Drug Delivery Market, By Route Of Administration, 2010 - 2017
  • Table 4 North American Oral Drug Delivery Market, By Technology, 2010 - 2017 ($Million)
  • Table 5 North American Oral Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 6 Controlled Release Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 7 Odt & Taste-Masking Market, By Country, 2010 - 2017 ($Million)
  • Table 8 Other Oral Drug Delivery Technologies Market, By Country, 2010 - 2017 ($Million)
  • Table 9 North American Pulmonary Drug Delivery Market, By Device Type, 2010 - 2017 ($Million)
  • Table 10 North American Pulmonary Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 11 Comparative Overview Of Pulmonary Drug Delivery Devices
  • Table 12 Metered Dose Inhalation Market, By Country, 2010 - 2017 ($Million)
  • Table 13 Dry Powder Inhalation Market, By Country, 2010 - 2017 ($Million)
  • Table 14 Nebulizers Market, By Country, 2010 - 2017 ($Million)
  • Table 15 North American Transdermal Drug Delivery Market, By Mode Of Delivery, 2010 - 2017 ($Million)
  • Table 16 North American Transdermal Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 17 Passive Transdermal Drug Delivery Market, By Technology, 2010 - 2017 ($Million)
  • Table 18 Passive Transdermal Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 19 Active Transdermal Drug Delivery Market, By Technology, 2010 - 2017 ($Million)
  • Table 20 Active Transdermal Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 21 North American Injectable Drug Delivery Market, By Product Type, 2010 - 2017 ($Billion)
  • Table 22 North American Injectable Drug Delivery Market, By Country, 2010 - 2017 ($Billion)
  • Table 23 Conventional Injection Devices Market, By Product, 2010 - 2017 ($Billion)
  • Table 24 Conventional Injection Devices Market, By Country, 2010 - 2017 ($Billion)
  • Table 25 Self-Injection Devices Market, By Product, 2010 - 2017 ($Million)
  • Table 26 Self-Injection Devices Market, By Country, 2010 - 2017 ($Million)
  • Table 27 Other Injectors Market, By Country, 2010 - 2017 ($Million)
  • Table 28 North American Ocular Drug Delivery Market, By Formulation, 2010 - 2017 ($Million)
  • Table 29 North American Ocular Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 30 Eye Drop Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 31 Ointment & Gel Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 32 Other Ocular Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 33 North American Nasal Drug Delivery Market, By Formulation, 2010 - 2017 ($Million)
  • Table 34 North American Nasal Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 35 Nasal Spray Market, By Country, 2010 - 2017 ($Million)
  • Table 36 Nasal Inhaler Market, By Country, 2010 - 2017 ($Million)
  • Table 37 Nasal Drops Market, By Country, 2010 - 2017 ($Million)
  • Table 38 Other Nasal Delivery Formulations Market, By Country, 2010 - 2017 ($Million)
  • Table 39 North American Topical Drug Delivery Market, By Formulation, 2010 - 2017 ($Million)
  • Table 40 North American Topical Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 41 Semi-Solid Topical Formulation Market, By Country, 2010 - 2017 ($Million)
  • Table 42 Liquid Topical Formulation Market, By Country, 2010 - 2017 ($Million)
  • Table 43 Solid Topical Formulation Market, By Country, 2010 - 2017 ($Million)
  • Table 44 North American Implantable Drug Delivery Market, By Device, 2010 - 2017 ($Million)
  • Table 45 Implantable Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 46 Drug-Eluting Stents Market, By Country, 2010 - 2017 ($Million)
  • Table 47 Implantable Infusion Pumps Market, By Country, 2010 - 2017 ($Million)
  • Table 48 Contraceptive Implants Market, By Country, 2010 - 2017 ($Million)
  • Table 49 Intravitreal Implants Market, By Country, 2010 - 2017 ($Million)
  • Table 50 Brachytherapy Seeds Market, By Country, 2010 - 2017 ($Million)
  • Table 51 North American Transmucosal Drug Delivery Market, By Mucosa Type, 2010 - 2017 ($Million)
  • Table 52 North American Transmucosal Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 53 Oral Transmucosal Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 54 Other Transmucosal Drug Delivery Technologies Market, By Country, 2010 - 2017 ($Million)
  • Table 55 North American Drug Delivery Market, By Country, 2010 - 2017 ($Million)
  • Table 56 U.S.: Drug Delivery Technologies Market, By Route Of Administration, 2010 - 2017 ($Million)
  • Table 57 U.S.: Oral Drug Delivery Market, By Technology, 2010 - 2017 ($Million)
  • Table 58 North American Pulmonary Drug Delivery Market, By Device Type, 2010 - 2017 ($Million)
  • Table 59 U.S.: Transdermal Drug Delivery Market, By Mode Of Delivery, 2010 - 2017 ($Million)
  • Table 60 U.S.: Injectable Drug Delivery Market, By Technology, 2010 - 2017 ($Million)
  • Table 61 U.S.: Ocular Drug Delivery Market, By Formulation, 2010 - 2017 ($Million)
  • Table 62 U.S.: Nasal Drug Delivery Market, By Formulation, 2010 - 2017 ($Million) 155
  • Table 63 U.S.: Topical Drug Delivery Market, By Formulation, 2010 - 2017 ($Million)
  • Table 64 U.S.: Implantable Drug Delivery Market, By Device Type, 2010 - 2017 ($Million)
  • Table 65 U.S.: Transmucosal Drug Delivery Market, By Mucosa Type, 2010 - 2017 ($Million)
  • Table 66 Canada: Drug Delivery Market, By Route Of Administration, 2010 - 2017 ($Million)
  • Table 67 Canada: Oral Drug Delivery Market, By Technology, 2010 - 2017 ($Million)
  • Table 68 Canada: Pulmonary Drug Delivery Market, By Device Type, 2010 - 2017 ($Million)
  • Table 69 Canada: Transdermal Drug Delivery Market, By Mode Of Delivery, 2010 - 2017 ($Million)
  • Table 70 Canada: Injectable Drug Delivery Market, By Technology, 2010 - 2017 ($Million)
  • Table 71 Canada: Ocular Drug Delivery Market, By Formulation, 2010 - 2017 ($Million)
  • Table 72 Canada: Nasal Drug Delivery Market, By Formulation, 2010 - 2017 ($Million)
  • Table 73 Canada: Topical Drug Delivery Market, By Formulation, 2010 - 2017 ($Million)
  • Table 74 Canada: Implantable Drug Delivery Market, By Device Type, 2010 - 2017 ($Million)
  • Table 75 Canada: Transmucosal Drug Delivery Market, By Mucosa Type, 2010 - 2017 ($Million)
  • Table 76 Mergers & Acquisitions, 2011 -2013
  • Table 77 Agreements, Collaborations, Joint Ventures & Partnerships, 2011 -2013
  • Table 78 New Product Launch, 2010 - 2012
  • Table 79 Other Developments, 2010 - 2013
  • Table 80 3M Company: Total Revenue, By Segment, 2009 - 2011 ($Million)
  • Table 81 3M Company: Total Revenue, By Geography, 2009 - 2011 ($Million)
  • Table 82 Baxter International: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 83 Baxter International: Medical Products Total Revenue, 2010 - 2012($Million)
  • Table 84 Baxter International: Total Revenue, By Geography, 2010 - 2012 ($Million)
  • Table 85 Becton, Dickinson: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 86 Becton, Dickinson: Medical Division Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 87 Becton, Dickinson: Total Revenue, By Geography, 2010 - 2012($Million)
  • Table 88 Catalent Pharma Solutions: Total Revenue, By Segment, 2009 - 2011 ($Million)
  • Table 89 Teva Pharmaceutical Industries Limited: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 90 Teva Pharmaceutical Industries Limited: Total Revenue, By Geography, 2010 - 2012 ($Million)
  • Table 91 Endo Health Solutions, Inc.: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 92 Johnson & Johnson, Inc.: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 93 Johnson & Johnson, Inc.: Total Revenue, By Geography, 2010 - 2012 ($Million)
  • Table 94 The Dow Chemical Company: Total Revenue, By Segment, 2010 - 2012 ($Million)
  • Table 95 Valeant Pharmaceuticals: Total Revenue, By Geography, 2010 - 2012 ($Million)

List of Figures

  • Figure 1 North America Drug Delivery Market, By Route Of Administration (2012)
  • Figure 2 Drug Delivery Market Segmentation
  • Figure 3 Market Dynamics
  • Figure 4 Porter's Five Forces Analysis For Drug Delivery Market
  • Figure 5 Value Chain Analysis
  • Figure 6 U.S. Pulmonary Drug Delivery: Market Share Analysis, By Key Player, 2012
  • Figure 7 Canada Pulmonary Drug Delivery: Market Share Analysis, By Key Player, 2012
  • Figure 8 U.S. Transdermal Drug Delivery: Market Share Analysis, By Key Player, 2012
  • Figure 9 Canada Transdermal Drug Delivery: Market Share Analysis, By Key Player, 2012
  • Figure 10 U.S. Injectable Drug Delivery Devices Market, By Key Players, 2012
  • Figure 11 Canada Injectable Drug Delivery Devices Market, By Key Players, 2012
  • Figure 12 U.S. Implantable Drug Delivery: Market Share Analysis, By Key Player, 2012
  • Figure 13 Canada Implantable Drug Delivery: Market Share Analysis, By Key Player, 2012
  • Figure 14 Opportunity Matrix: North America Drug Delivery Market (2012)
  • Figure 15 Oral Drug Delivery Market Share (2012)
  • Figure 16 Key Growth Strategies, 2010 - 2013
  • Figure 17 3M Company: Total Revenue And R&D Expenses, 2009 - 2011 ($Million)
  • Figure 18 Aptalis Pharma, Inc.: Total Revenue And R&D Expenses, 2009 - 2011 ($Million)
  • Figure 19 Baxter International: Total Revenue And R&D Expenses, 2010 - 2012 ($Million)
  • Figure 20 Becton, Dickinson: Total Revenue And R&D Expenditure, 2010 - 2012 ($Million)
  • Figure 21 Catalent Pharma Solutions: Total Revenue And R&D Expenses, 2009 - 2011 ($Million)
  • Figure 22 Teva Pharmaceutical Industries Limited: Total Revenue And R&D Expenses, 2010 - 2012 ($Million)
  • Figure 23 Endo Health Solutions, Inc.: Total Revenue And R&D Expenses, 2010 - 2012 ($Million)
  • Figure 24 Johnson & Johnson, Inc.: Total Revenue And R&D Expenses, 2010 - 2012 ($Million)
  • Figure 25 Nektar Therapeutics, Inc.: Total Revenue And R&D Expenses, 2009 - 2011 ($Million)
  • Figure 26 Psivida Corporation: Total Revenue, 2009 - 2011 ($Million)
  • Figure 27 The Dow Chemical Company: Total Revenue And R&D Expenses, 2010 - 2012 ($Million)
  • Figure 28 Valeant Pharmaceuticals: Total Revenue And R&D Expenses, 2010 - 2012 ($Million)
Back to Top